Affimed's AFM13 In Combination With NK Cells Show Improved Tumor Recognition, Killing In Preclinical Studies

Affimed NV AFMD has announced the publication of in vitro and in vivo research of its lead innate cell engager (ICE), AFM13 (CD16A/CD30), combined with healthy donor-derived Natural killer (NK) cells, in Clinical Cancer Research.
The preclinical data demonstrated that AFM13 strongly binds to NK cells, including cytokine-activated or cord blood-derived NK (cbNK) cells, resulting in enhanced tumor recognition and antibody-dependent cellular cytotoxicity.
The preclinical data published supported the Investigational New Drug (IND) application for the ongoing Phase 1 study of AFM13, precomplexed with cytokine-preactivated cbNK cells followed by AFM13 monotherapy in patients with CD30-positive malignancies.
Results as of March demonstrated an objective response rate of 100% (overall response rate=4/4; partial response=2/4; complete response=2/4) among the first patients enrolled who were all heavily pretreated.
There were no observed events of cytokine release syndrome, neurotoxicity, or graft-versus-host disease.
Price Action: AFMD shares are trading 0.79% lower at $8.79 during the premarket session on the last check Friday.